AtriCure (ATRC) Projected to Release Earnings on Tuesday

AtriCure (NASDAQ:ATRC) will likely be announcing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect AtriCure to post earnings of ($0.0485) per share and revenue of $151.05 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

AtriCure Stock Down 0.4%

NASDAQ:ATRC opened at $60.87 on Tuesday. AtriCure has a twelve month low of $25.36 and a twelve month high of $61.70. The company has a market cap of $3.10 billion, a price-to-earnings ratio of 289.85 and a beta of 1.24. The stock has a fifty day simple moving average of $54.36 and a 200-day simple moving average of $37.75. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director owned 14,015 shares of the company’s stock, valued at approximately $538,456.30. The trade was a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Salvatore Privitera sold 4,519 shares of the company’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00. Following the transaction, the insider owned 142,745 shares of the company’s stock, valued at $8,564,700. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 43,868 shares of company stock worth $2,138,617. 4.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ATRC has been the subject of several research analyst reports. Needham & Company LLC lifted their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Freedom Capital cut AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. BTIG Research raised their price objective on AtriCure from $55.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Finally, UBS Group lowered AtriCure from a “buy” rating to a “sell” rating in a research report on Wednesday, October 21st. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $55.70.

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.